Compare CCLD & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCLD | ICCC |
|---|---|---|
| Founded | 1999 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.6M | 93.1M |
| IPO Year | 2013 | 1995 |
| Metric | CCLD | ICCC |
|---|---|---|
| Price | $2.47 | $9.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 463.1K | 27.5K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 135.71 | 53.85 |
| EPS | N/A | ★ 0.41 |
| Revenue | ★ $120,499,000.00 | $26,493,169.00 |
| Revenue This Year | $11.49 | N/A |
| Revenue Next Year | $7.95 | N/A |
| P/E Ratio | ★ N/A | $24.24 |
| Revenue Growth | 8.72 | ★ 51.64 |
| 52 Week Low | $2.03 | $4.52 |
| 52 Week High | $3.98 | $12.10 |
| Indicator | CCLD | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 42.02 |
| Support Level | $2.07 | $9.36 |
| Resistance Level | $3.14 | $10.75 |
| Average True Range (ATR) | 0.14 | 0.45 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 27.72 | 29.56 |
CareCloud Inc delivers flexible, tech-enabled solutions for healthcare providers of all sizes and multi-specialties across the U.S. It is a healthcare technology company offering cloud-based solutions that simplify clinical, administrative, and financial workflows for medical practices of all sizes. Its comprehensive suite includes Electronic Health Records (EHRs), Practice Management, Revenue Cycle Management (RCM), Medical Billing, Telehealth, and Patient Experience solutions. The group helps practices increase efficiency, improve patient care, and drive sustainable growth-all while ensuring HIPAA compliance and seamless integration. The operating segments of the group are Healthcare IT, which is the key revenue-generating segment, and Medical Practice Management.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.